Okulo (t/a OKKO Health) secures £2 million Pre-Seed investment led by Dieter von Holtzbrinck Ventures
Summary
Played regularly, the game can inform clinicians, and patients, of changes in visual acuity, sensitivity to contrast, distortion, and colour vision. The funding supports the creation of new aggregate datasets, providing opportunities to better understand how to target treatments for macular degeneration through the deployment of AI in the form of machine learning algorithms. Its launch in Germany will enable the gathering of market evidence for national reimbursement, a novel aspect of the German health care system, through studies in hospitals & clinics.Speaking of the funding, Fabian von Trotha from DvH Ventures said:Dr. Claire Novorol, Chair of the OKKO Board, who also holds the role Co-founder and Chief Medical Officer at Ada Health, added:This funding round brings OKKO one step closer to our vision of patient enablement and precision ophthalmology. This hardware-free solution runs as a simple video game app for ophthalmology patients to play at home, using the sensors in the phone to accurately measure features of their vision. For patients, this means that eye health can be tracked between in-person clinic visits, and ultimately will lead to personalised and remote care.
Funding
Review available funding amount, funding date, investors, and linked company information related to Okulo (t/a OKKO Health) secures £2 million Pre-Seed investment led by Dieter von Holtzbrinck Ventures in the interactive ISVWorld profile.